Advent to sell generic drugmaker Zentiva to GTCR
Advent acquired Zentiva from Sanofi in 2018 and transformed the company into a highly successful standalone business
Advent acquired Zentiva from Sanofi in 2018 and transformed the company into a highly successful standalone business
NouvNeu001 is the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive this designation
Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
The $700 million project is part of Roche’s $50 billion investment in US manufacturing, infrastructure and R&D
Collaboration reinforces Boehringer Ingelheim’s expertise in microbial contract development and manufacturing
Rocket will also collaborate with investigators to implement an immunomodulatory regimen more closely reflecting that administered in the Phase 1 pediatric cohort
The operating profit (EBITDA) rose 20.7% to Rs. 156.4 crore
Athena is also exploring the use of this technology for expanded carrier screening
Subscribe To Our Newsletter & Stay Updated